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Principles of Whole Organ Transplantation 
THE EVOLUTION of whole organ transplantation has been one of 
the most remarkable chapters in the history of medicine and one 
of the least expected. In 1961, the Nobel Laureate Burnet wrote 
in the New England Journal of Medicine that " ... much 
thought has been given to ways by which tissues or organs not 
genetically and antigenically identical with the patient might be 
made to survive and function in the alien environment. On the 
whole, the present outlook is highly unfavorable to suc-
cess. . . ."6 This pessimistic view was published scarcely more 
than a vear before the avalanche of successful clinical renal trans-
plantations in 1962 and 1963 that extended such procedures be-
yond the seemingly exotic identical and fraternal twin cases of 
the mid and late 1950s. 
The principles of whole organ transplantation were developed 
with the simple kidney model. However, it was natural that 
transplantation technology would be applied to the grafting of 
other organs, including the liver, heart, lung, heart plus lung, 
pancreas, spleen, and intestines. In this chapter, we will exam-
ine the ingredients of these astonishing developments during the 
last two decades, speculate about how the momentum of this 
progress can be sustained and accelerated, and point out how 
transplantation technology is apt to influence pediatric surgery in 
the years ahead. In so dOing, we will consider immunosuppres-
sion, tissue matching, and organ procurement (and preservation) 
in that order. The surgical technique for specific organ transplan-
tations is discussed in other chapters. 
Immunosuppression 
Immunosuppression is the unique feature of whole organ 
transplantation. In describing the first successful case of identical 
twin transplantation in 1956, Merrill et al. 30 wrote, "Tissue trans-
plantation including that of a functioning kidney appears to he a 
feasible procedure in identical twins, but to date successful per-
manently functioning homografts appear to be limited to such 
individuals." The statement reflected acceptance of Medawar's2h 
thesis that rejection was an immunologic phenomenon as well as 
an acknowledgment that there was no known way to prevent this 
process. 
Therapeutic Beginnings 
Yet by 1960, the possibility of weakening the recipient im-
mune process with corticosteroids,4 total body irradiation, 14. 2,; or 
the cytotoxic drug 6-mercaptopurine7 . 46 or its imidazole deriva-
tive, azathioprine,8 had been established in animals. Sporadic at-
tempts to use these techniques for renal homotransplantation in 
humans were so unsuccessful33, 34, 80 that it was widely thought 
that the immunosuppression requisite to prevent rejection would 
inevitably lead to immunologic invalidism and lethal infections. 
Double-Drug Therapy 
Renal transplantation became a practical reality in 1962 and 
1963 with the marriage of corticosteroid therapy (prednisone or 
prednisolone) to baseline therapy with azathioprine (Table 
38_1).49,61 The use of this synergistic drug combination, which 
quickly found its way into the other principal transplantation 
centers of the day,19 permitted fundamental observations to be 
made, including the fact that rejection was a reversible process. 61 
With the passage of time after the operation, a change in the 
relation between the graft and the host often occurred, permit-
ting eventual reduction of drug doses. 49. 61 Patients who did not 
require chronic high-dose corticosteroid therapy to retain their 
grafts could return to useful social and vocational function and 
without the fear of immunologic invalidism. The double-drug 
therapy with azathioprine and prednisone remained the gold 
standard of transplantation for many years. 
TABLE 38-1.-CLINICAL h1MUNOSl'PPHESSIVE DRUG REGIMENS DEVELOPED WITH KIDNEY 
TRA"ISPLANTATIO,", ~"a USED FOR OTHER ORGANS 
YEAR DESCRIBED l.'SED FOR EXTRARENAL 
,(;ENTS AND REPORTED PLACE DEFICIENCIES TRANSPLANTATION 
Azathioprine 196233,34 Boston Ineffective, dangerous No 
Azathioprine-corticosteroids 196349,61 Denver Suboptimal Yes 
Thoracic duct drainage as 19631,. Stockholm Nuisance; requires 20-30 days Yes 
adjunct pretreatment 
ALGt as adjunct 196659 Denver Still suboptimal Yes 
Cyclophosphamide 197063 Denver No advantage except for patients Yes 
substitution for with azathioprine toxicity 
azathioprine 
Total lymphoid irradiation 197933 6H Palo Alto, Calif., Dangerous; extensive preparation; No 
\iinneapolis not quickly reversible 
Cvclosporine alone 1978-79" Cambridge. England Suboptimal Yes 
Cyclosporine- 1980"" Denver Under evaluation Yes 
Corticosteroids 
'It was not realized until much later that pretreatment for 3-4 weeks before transplantation was a necessary condition. 6., 
tAn tilymphocyte globulin. 
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Triple-Drug Therapy 
Changes made during the next 16 years (see Table 38-1) con-
sisted of modifications of. or additions to, the original double-
drurr treatment. Most of the modifications were designed to blu~t the attack of the lymphocytes, which had been recognized 
as the mediators of rejection. The most significant addition was 
the use of antilymphocyte globulin (ALe) as an adjunct to aza-
thioprine and prednisone .. 59 The ALe consisted of antibodies 
against human lymphoid tissue, which were raised in horses, 
rabbits, goats, or other animals by immunizing them to human 
lymphocytes. When thymic lymphocytes were used for immuni-
zation, the product was called antithymocyte globulin (ATe). 
The antibody-containing globulin was extracted, purified, and 
made readv for intramuscular or intravenous use. 
The use' of the ALe or ATe was limited to the first few post-
operative weeks or months, because the foreign animal globulin 
evoked an immune response from the treated patients, mani-
fested as immune elimination of the globulin or, worse, anaphy-
lactic and other dangerous immunologic side effects. Neverthe-
less, an improved quality of immunosuppression was obtained by 
adding ALG to azathioprine and prednisone. 37. 59 In recent years, 
there has been much interest in using ALe for the specific in-
dication of rejection. It was shown 15 years ago that ALe could 
rescue rejecting kidney and liver grafts in dogs many days after 
transplantation as effectively as if ALe treatment had been used 
from the outset, 50 and this concept has been the basis of manv 
successful clinical trials 67 . 
In spite of its great potential value, ALG has not been univer-
sally employed as a part of the antirejection armamentarium be-
cause of several limiting features noted in Table 38-2, including' 
the fact that the globulin has been in no sense a standardized 
agent. The problems with standardization could be eliminated 
with the new hybridoma technology introduced by Kohler and 
Milstein.23 With hybridoma cells injected into the peritoneum of 
mice, a homogeneous (monoclonal) antihuman-lymphocyte anti-
body can be produced. Therapy with monoclonal antibodies was 
introduced into clinical medicine by Cosimi et aI., 12 who admin-
istered the so-called OKT3 antibodies, which selectively deplete 
T-lymphocvtes and cause lymphopenia. The objective was to re-
verse kidney graft rejection that was nonresponsive or poorly re-
sponsive to corticosteroid therapy. The features of the OKT3 an-
tibodies are summarized in Table 38-2, including the side 
reactions. 
The possibility that a safer and more specific kind of mono-
clonal antibodv can be developed was raised in a recent report 
by T akahashi ~t al. 69 They described a new kind of mouse mono-
clonal antibody (see Table 38-2) derived from independent hy-
bridomas and directed against lymphoid blast cells of the kind 
that invade grafts. In animals and in preliminary clinical trials in 
Japan,69 these putative CBL antibodies have consistently re-
versed established renal homograft rejection without causing 
lymphopenia or any toxic manifestations. The features of the 
CBL antibodies are summarized in Table 38-2. The blast cell 
specificity is explained by the nature of the immunogen. Spleen 
cells from Balb/C mice immunized three times against human 
leukemia cell lines are removed and fused with myeloma cells; 
10,000,000 hybridoma cells are injected intraperitoneally in 
mice, and the monoclonal antibody-rich ascites is harvested in 
2-3 weeks. 
It will be surprising if monoclonal ALe does not play an im-
portant role in immunosuppressive practice in the future. Less 
discriminating techniques of lymphoid depletion have been used 
clinically in the last two decades (see Table 38-1), includin& thy-
mectomy,49 splenectomy, 49 total lymphoid irradiation,35. and 
thoracic duct drainage (TDD).17.65 These have been virtually 
abandoned, largely because of their inconvenience, dangers, un-
proved value, or various combinations of these factors. 
For a number of years, it was considered that azathioprine was 
the one essential drug upon which effective immunosuppression 
depended. This dogma was overthrown by the demonstration in 
1970 that cyclophosphamide, the commonly used cancer che-
motherapeutic agent, could be freely substituted for azathio-
prine. 63 In an academic sense, this was an important observation, 
because cyclophosphamide had been thought to be an anti B-
lymphocyte drug, whereas azathioprine was thought to have con-
siderable T-Iymphocyte specificity. From a practical point of 
view, cyclophosphamide was no better than azathioprine, and 
because its side effects were substantial, its use has been re-
stricted to substitution for azathioprine for the indication of idio-
syncratic reactions to the latter drug. 
Years of Consolidation (1963-1980) 
The results obtainable with the immunosuppression tech-
niques available by 1963 represented a quantum leap from a zero 
potential of renal transplantation to a broadly applicable proce-
dure. Almost from the beginning, using the original double-drug 
therapy, it was possible to obtain a 70% I-year graft survival after 
intrafamilial transplantations without good histocompatibility 
TABLE 38-2.-KINDS OF ALes 
Standardized 
Target cells 
Amount heterologous protein 
injected in adult/day 
Irrelevant antibodies 
Lymphopenia 
Chills, fever 
Antiforeign protein 
antibodies evoked in 
patient 
Rejection reversal incidence 
*Antilymphocyte globulin. 
tAntithymocyte globulin. 
CONVEl\TIONAL 
ALC" OR ATCt37, 50. 59. 67 
No 
All lymphocytes 
500-1,000 mg 
99% 
Usual 
Common 
Yes 
65% 
OKT3 
MONOCLONAL12 CBL MONocLoNALI169 
Yes Yes 
T -lymphocytes Immunoblasts invading 
grafts 
5 mg 5 mg 
50% < 50% 
Invariable :-lever 
Invariable Never 
Yes Expected 
88% 89% 
liThe conclusions about CBL antibodies have not yet been confirmed. 
matching.49, 61, 66 With the use of triple-drug regimens (which 
had in common the lymphoid depleting procedures), the I-year 
related graft survival could be pushed up to 85% or 
higher. 37, 59, 66 
The limitations of all of the aforementioned kinds of immuno-
suppression were most clearly exposed when nonrelated donors 
(for the most part cadavers) were used. 66 The United States' na-
tional expectations of cadaver renal graft survival were shown by 
Opelz et al. 38 and by others27 to be in the 50% range, even in 
recent times, The main achievement until 1980 was the reduc-
tion in patient mortality, which in part resulted from return of 
many patients to dialysis in the event of a graft rejection, Very 
low patient mortality was reported by centers that followed the 
philosophy of giving up kidneys early if complications ensued, 
but I-year cadaver kidney graft survivals were reported as low as 
40%.75 Others with cadaver graft survival as high as 60% or 65% 
reported an exceptionally high patient mortality.37 What was 
being done was to delineate the biologic limitations of the so-
called conventional techniques of immunosuppression available 
at those times. These limitations were so extreme that transplan-
tation of other cadaver organs such as the liver, heart, lung, and 
pancreas remained unpredictable and eXferimental. 
It has been shown by Opelz et al. 3 and Terasaki and his 
associates73 that graft survival after cadaver kidney transplanta-
tion can be improved by preparing the recipient with whole 
blood transfusion. It is possible that some kind of accidental en-
hancement is thereby achieved. However, part of the explana-
tion of this effect is that patients with a high capacity of immu-
nologic response are sensitized by multiple transfusions and 
develop wide reacting antibodies that preclude consideration for 
renal transplantation, because donors who have a negative cross-
match with such recipients can no longer be found. The result is 
to exclude selectively such unfavorable candidates from the re-
cipient pool. As many as a third of multiple transfused recipients 
can follow this tragic pathway. For this reason, many renal trans-
plant surgeons have been opposed to the transfusion preparation, 
but its wide use has contributed to the growing numbers of non-
transplantable patients who have become a burden in all active 
renal dialysis programs, For potential recipients of extrarenal or-
gans, such deliberate preparation by transfusion is even less ac-
ceptable. An example would be a potential cardiac recipient for 
whom the option of artificial organ support analogous to dialysis 
does not exist. Accidental sensitization by blood transfusions with 
consequent antibody formation and the inability to find a donor 
would eliminate consideration of transplant candidacy, Thus, re-
cipient preparation with transfusions is not a satisfactory means 
to improve graft survival. 
The watershed year for improved organ transplantation was 
1978. In that year, there were at least three possible ways in 
which it was envisioned that immunosuppression could be im-
proved, One was with TDD as an adjunct. 65 A second possible 
new technique was with total lymphoid irradiation , 35, 68 a proce-
dure upon which we will spend little time, because it has been 
largely abandoned (see Table 38-1), The third possibility of im-
proving the prospects of transplantation was with an interesting 
drug then called cyclosporin-A (now cyclosporine). Many great 
expectations of transplantation for the future rest with cyclospor-
ine. 
The Cyclosporine Era 
Cyclosporine is a fungus extract that was discovered and char-
acterized to an unusually complete degree by scientists of the 
Sandoz Corporation in Basel, Switzerland, The basic immuno-
logic studies were performed by Borel et al., 5 who proved the 
impressive immunosuppressive qualities of this agent in a num-
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ber of autoimmune models in rodent experiments as well as with 
skin homografts in mice. The first clinical trials with cyclosporine 
for solid organ transplantation were undertaken by CaIne and his 
associates9 at Cambridge in the middle of 1978. From their ef-
forts came one of the most important publications in the history 
of transplantation. 
Their article contained both good and bad news. 9 The good 
news was that transplantation of a number of cadaver kidneys 
and a few livers and pancreases had been carried out successfully 
without any corticosteroid therapy, This was an achievement 
never before consistently attainable with any other single agent. 
The bad news was that there had been an unacceptably high 
patient mortality, that three of the 34 recipients whose cases 
were reported had developed lymphomas, and that none of the 
kidney recipients had achieved normal renal function. Thus, the 
report was tantalizing, but its publication just before the first 
clinical trials in the United States were scheduled created great 
pressure to abort the American trials. Two trials were neverthe-
less undertaken. One restricted cyclosporine to the first 2 post-
operative months, after which it was replaced by azathioprine. lO 
The results were not satisfactory. 
At the University of Colorado, a full-scale trial proceeded.64 In 
the Colorado trial (since transferred to Pittsburgh), it was real-
ized at once that cyclosporine could not prevent rejection sys-
tematically when used alone, and that the optimal exploitation of 
the -drug would require ancillary treatment with corticoste-
roids. 64 Although the treatment schedules were not fully stan-
dardized at that time, the I-year primary cadaver graft survival 
in the pilot trials at Colorado was nearly 80%.57 In the follOWing 
year, a randomized trial comparing cyclosporine-corticosteroid 
therapy with therapy by azathioprine and prednisone was carried 
out. A I-year graft survival in the experimental group was 90% 
vs. the expected 50% in the "controls."45 
The patterns of convalescence that could be expected after ca-
daver renal transplantation under cyclosporine-corticosteroid 
therapy were clearly delineated, and algorithms were developed 
to guide therapy. 51 The kinds of convalescence that could be ex-
pected were divided into Class 1 (good graft function and no 
secondary deterioration), Class 2 (initial graft function with later 
deterioration), and Class 3 (anuria from the outset). Each of these 
kinds of recovery required a different approach to immuno-
suppression, in which the main maneuverability was by adjust-
ments of the corticosteroid doses. The details of the treatment 
plan are beyond the scope of this chapter. Suffice it to say, with 
the appropriate attention to details of cyclosporine-corticosteroid 
management, cadaver renal transplantation became overnight a 
spectacularly successful way of treating end-stage renal disease. 
An extremely important additional observation with cyclospor-
ine-corticosteroid therapy has been that cadaver kidney retrans-
plantation has been two or three times more successful than in 
the past with conventional immunosuppression, and with a pa-
tient mortality that has been less than 5%. With this latter ob-
servation, the temptation has been removed to overtreat recipi-
ents of primary kidney grafts who are having difficulties with 
unusually severe or persistent rejection. In such cases, the graft 
should be written off and removed, realizing that the patient has 
essentially as good a chance after retransplantation as on the 
original occasion. 
The major improvements in renal transplantation made possi-
ble with cyclosporine-corticosteroid therapy will necessitate a re-
vision of the strategies and policies of renal transplantation that 
have slowly evolved over the years. First, the widespread use of 
living related donors, which has been justified in the past on the 
basis of results better than those with cadaver transplantation, 
will become obsolete. There have been a number of donor 
deaths throughout the world after living related transplantation, 
-_ .. _---------------
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probably about 2.0 in totaL This is a very small fraction of the 
total number of living related donors, but any mortality repre-
sents a penalty, however small, that is no longer justified if 
equivalent results can be obtained using cadaver kidneys. 
Second, tissue typing, which in nonrelated cases has never 
been a major factor in donor selection (at least with matching at 
the A and B loci), will be even less important. In the trials of 
cadaver transplantation under cyclosporine-corticosteroid ther-
apy, the donor-recipient matching was random or nearly so and, 
consequently, the matches at the A, B, and Dr loci were uni-
formly bad. This indicated the ability of cyclosporine-corticoste-
roid therapy to override histoincompatibility and other poten-
tiallv adverse immunologic factors to an extraordinary degree 
(see' later section). 
However, cyclosporine-corticosteroid therapy cannot prevent 
the hyperacute rejection of kidneys that is mediated by pre-
formed cytotoxic recipient antibodies (see later). This means that 
antibody analysis of recipient sera and donor-recipient cross-
matching will be as important as ever, and perhaps more so. 
Poor-risk patients, including diabetics, will become increasingly 
more attractive candidates, because they can be treated without 
the penalties of chronic high-dose corticosteroid therapy. 
The interface between dialysis and transplantation will become 
altered in future years, a point of particular importance in coun-
tries like the United States in which both of these alternative 
kinds of therapy are so well developed. 
Extrarenal Whole Organ Transplantation 
To fully exploit the advances in immunosuppression, even for 
kidney transplantation, will require an increased supply of or-
gans, which each region will have to generate on behalf of its 
own citizens. The importance of a supply of cadaver donors ex-
tends far beyond the field of nephrology. The application of what 
has been learned about immunosuppression to the transplanta-
tion of cadaver organs other than the kidney has been a natural 
event,55 as will be emphasized in subsequent chapters, and one 
that is certain to change the character of pediatric surgery. 
Special Considerations in Children 
When clinical renal transplantation was made feasible in 1962 
and 1963 by the combined use of azathioprine and predni-
sone,49.61 there were expressions of concern about subjecting 
children to such drastic therapy. 44 However, the first report of 
consistent success in treating infants and children49,58 was 
promptly confirmed,16. 18. 36, 79 although acceptable results were 
obtained only with consanguineous donors. A number of special 
pediatric transplantation centers were established24. 26. 43 at 
which there usually has been a major effort to find genetically 
related donors. Failure to do so, and consequent transplantation 
of cadaver kidneys, has been associated with a higher incidence 
of graft loss, death, and unacceptable morbidity from chronic 
high-dose corticosteroid therapy. With organs such as the liver 
and heart, there has been no option but the cadaver donor. Ma-
jor progress in cadaver transplantation was stalled for almost two 
decades, despite efforts at tissue typing, better understanding of 
rejection, and the modest improvements in immunosuppression 
summarized in Table 38-1 up to the cyclosporine era. The inhi-
bition of normal growth in infants and children, whose mainte-
nance corticosteroid requirements were high, was a special 
source of concern. 
When cyclosporine was first tested, it was not available for 
evaluation in patients under 18 years of age because of the un-
known risks from side effects. The initial fear that. there might 
be an exorbitant incidence of de novo lymphomas9 has proved 
unfounded. Other side effects, including nephrotoxicity, hepa-
totoxicitv, hirsutism, motor dyskinesias, and gum hyperplasia, 
have be~n manageable by dose adjustments!,551. '7. 04 Further-
more, it has become obvious in children that normal growth and 
development can be expected in cadaver organ recipients under 
cyclosporine-corticosteroid therapy, because the maintenance 
corticosteroid doses have been low.''>4 Most of the infants and 
children who have received cadaver kidneys, livers, and hearts 
appear normal. 
These results and observations have made us believe that 
transplantation of a variety of cadaver organs increasingly will 
become a practical and attractive reality in more pediatric health 
care centers. 21 .. 54 In fact, it is hard to envision a tertiary pediatric 
hospital without such a capability. 
Tissue Typing 
Antigen Matching 
At the beginning of this chapter, the earlier opmlOns of 
Burnet6 and Merrill et al:30 were cited about the impossibility or 
implausibility of organ transplantation without genetic identity. 
In the first identical twin cases of renal transplantation, the ef-
forts that were made to be sure of genetic identity were extraor-
dinary and ultimately included skin grafting .. 30 It is no distortion 
of concept to say that the current tissue matching between do-
nors and recipients is an attempt to come as close as possible to 
the ideal circumstances of the original Boston identical twin 
cases. 
The possibility of tissue typing by serologic methods was 
raised by DausseeJ in 1958 in his description of antiwhite cell 
antibodies in certain human sera. The assumption was that the 
patients had been accidentally sensitized to white cell antigens. 
Payne and Rolfs41 expanded the serum donor pool by showing 
that multiparous women had a higher-than-average incidence of 
such antibodies, and, later, sensitization was deliberately caused 
by whole blood transfusion or the infusion of white blood cells. 
van Rood and van Leeuwen7R introduced computer technology 
to make sense of and to categorize the bewildering array of 
polyvalent antibodies found in the sera of such patients who had 
been aCcidentally or deliberately sensitized. 
A critical step in the painful process of antibody detection, 
collation, and classification was the develoNment of a microcvto-
toxicitv assav bv Terasaki and McClelland' in 1964. The cvtolv-
sis of test lymphocytes by such antisera indicated the pre~en~e 
of the same or similar antigens as those that originally sensitized 
the serum donor. Failure of such a reaction implied the absence 
of the antigen. It was appreciated from the beginning that many 
of the antisera reacted against the same or similar lymphocyte 
antigens. Between 1963 and 1968, these antisera were classified 
by direct testing and by computer techniques according to the 
specificity of action. Eventually, it became possible to define hu-
man lymphocyte histocompatibility antigens (HLA) against which 
groups of antisera reacted. By 1970, it was appreciated that there 
were probably two principal histocompatibility (HLA A and B) 
loci on the same chromosome and that the transmission of these 
loci, each containing two antigens, followed classic .\I1endelian 
law. In subsequent years, an additional locus, the so-called Dr 
locus, which may be the single most important determinant of 
cellular immunity, has been described.J2.42.77 
Although the story of the histocompatibility chromosome re-
quired nearly two decades to be fully played out, it was appre-
ciated by 1964 that the antigens being detected by the above-
described antibodies were probably part of the human histocom-
patibility system. Thus, it was natural to look for a correlation 
between the outcome after renal transplantation and the match 
of antigens between the donors and recipients. The first investi-
gation of this possibility was carried out by Dr. Paul Terasaki of 
Los Angeles on patients treated by us at the University of Colo-
rado. Because almost all of the kidneys were from living volun-
teers (70% related, 30% unrelated), most of the donors were also 
available for postoperative typing studies. The results did not 
show a strong influence of matching60 and defined a need for a 
prospective trial of tissue matching, which was the first such ef-
fort in the world. 74 
A powerful correlation could not be demonstrated between the 
quality of matching and the outcome. With Dr. Charles Hol-
grimson of the University of Colorado and Terasaki and his as-
sociates, we updated the interpretation of the cytotoxic specific-
ity of various sera, incorporating the new information acquired 
in the 1964-1969 study peliod. 
The revised donor and recipient HLA types were made as ac-
curate as could be achieved at that time for almost 200 cases with 
a minimum follow-up of at least 1 year. Study of the University 
of Colorado cases of renal transplantation with 2-year biopsies on 
all surviving patients included histologic examination of all tis-
sues by Professor K. A. Porter of St. Mary's Hospital and Medi-
cal School, London. The resulting histopathologic grades, plus 
tests of graft function, and the clinical success or failure of the 
transplantation provided objective criteria by which matching 
could be judged. 
The fact that the results were better in related than nonrelated 
transplantation was compatible with the conclusion from earlier 
studies about the relevance of HLA antigens to histocompatibil-
ity, but mainly because the supreme advantage in all the param-
eters studied was evident with perfectly matched sibling trans-
plantations. Within all other related donor transplantations, the 
quality of matching of the four antigens of the A and B loci 
seemed not to make a major difference in the outcome. In pa-
tients who had received nonrelated kidnevs, there was the same 
lack of correlation between typing and th~ outcome. 
The results precipitated a shudder throughout the typing 
world when they were presented at the American Society of N e-
phrology meeting, because the prospect of using HLA typing as 
an important instrument of donor-recipient matching (especially 
in cadaver cases) was seriously questioned for the first time. This 
information was annotated and represented at the American Sur-
gical Association on April 28, 1970.62 
Terasaki was not yet convinced of the validity of the conclu-
sions. Beginning in early 1970, he and his associates gathered 
data on some LOOO cadaver kidney cases from several centers for 
an analysis to be presented in September at the International 
Transplantation Society meeting in The Hague. The additional 
data did not change the message. The quality of matching as 
measured by the serologic techniques was not a reliable method 
to select a cadaver donor for any given recipient. 31 In very large 
series reported up to recent times, the percentage gain in I-year 
cadaver graft survival per antigen matched at the A and B loci 
has ranged from insignificant to 2 or 3 percentage points. 27,38 
Increasing the graft survival while at the same time reducing 
the risk in cadaver cases has become one of the great challenges 
of applied immunology. In more recent years, the discovery of 
the new Dr locus has reawakened hope that typing can be instru-
mental in improving the outlook of nonrelated recipients. 32.42,77 
However, it is probable that improvements in immunosuppres-
sion will be more important, as suggested in the first section of 
this chapter. The complexity of the histocompatibility system has 
proved to be so great that donor-recipient matching for many 
patients is not a realistic possibility. 
Detection of Preformed Antibody States 
In 1965, Terasaki et al. 71 described the first example of "hy-
peracute rejection." The authors explained the loss of a kidney 
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on the operating table by the action of cytotoxins in the recipi-
ent's serum, which were shown in retrospect to kill the lympho-
cytes of the kidney donor. The observation was confirmed by 
Kissmeyer-Nielsen et al. 22 of Denmark during the following year 
and by Terasaki's own team. 40 Since then, a vital role of tissue 
typers has been to prevent such immunologic calamities by in-
sisting upon a negative crossmatch when donor lymphocytes and 
other cells are crossmatched against recipient sera. 
Workers in Terasaki's laboratory have subsequently shown that 
of the variety of antibodies that could be detected in recipient 
sera, not all are harmful.15.20.70 The lymphocytotoxins that are 
associated with hyperacute rejection are of the IgG class and di-
rected against T-lymphocytes. Because they are detected at 37 
C, they have been termed the T-warm antibodies. 7o In contrast, 
warm antibodies of the IgG class directed against B-lymphocytes 
do not cause hyperacute rejection, and "cold" IgM antibodies 
may actually increase the chance of graft survival. 15,20,70,76 
Although a positive cytotoxic crossmatch is to be greatly feared 
in planning a renal transplantation, Ting76 has recently reviewed 
the circumstances in which a positive crossmatch may not lead 
to hyperacute rejection. It is important to emphasize that the full 
significance of a positive crossmatch and the conditions under 
which such a crossmatch can and cannot be accepted have not 
yet been thoroughly worked out. There is a great need for fur-
ther information about the Significance and nature of antibodies 
that either do or do not cause hyperacute rejection. Every major 
renal transplantation center in the world that has been in oper-
ation for more than a few months has a list of prospective cadaver 
kidney recipients who have become "untransplantable" by virtue 
of their preformed antibody status. Many of the tests that have 
condemned such recipients to a life on dialysis may eventually 
prove to be wrong. Even with those antibodies that cause hyper-
acute rejection, all hope may not be lost. Efforts have been made 
to prevent hyperacute rejection in patients with widely reacting 
T-warm antibodies by reducing the immunoglobulin concentra-
tion with thoracic duct drainage for a month or longer. A number 
of pharmacologic techniques have been used to prevent the 
abrupt destruction of homografts in these unfavored recipients, 
but to date none has been found satisfactory. 
Organ Procurement and Preservation 
A great increase can be expected in the demand for cadaver 
kidneys and other vital organs. Throughout the years, a uniform 
procedure has been developed that is flexible enough to allow 
the excision of various organ combinations without jeopardy to 
any of the individual grafts. 52 
In so-called heart-beating cadavers, studies can be obtained of 
the function of individual organs. Cardiovascular-respiratory in-
stability may be reflected in the necessity for vasopressor sup-
port, poor blood gas values, or other adverse findings common 
in patients in intensive care units. Most brain-dead donors can 
be maintained and improved with conventional intensive ther-
apy, and an attempt can then be made to coordinate the needs 
of transplant surgeons in different parts of the country. 
The Principle of Core Cooling 
The intraoperative infusion of cold fluids is the essential first 
step. With all organs, the guiding principle is avoidance of warm 
ischemia. This is achieved by carefully timed and controlled in-
fusion of cold solutions into anatomical regions, the limits of 
which are defined by preliminary dissection. 
Cooling of an organ graft by intravascular infusion of chilled 
lactated Ringer's solution at the time of circulatory arrest ex-
pands by many times the duration of organ viability and allows 
the unhurried application, if desired, of other more sophisticated 
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Fig 38-1.-Total midline incision used for multiple organ 
procurement. (Used by permission .52) 
preservation measures. The concept of core cooling was intro-
duced in the laboratory for liver transplantation 25 years ago56 
and promptly applied clinically for the preservation of the 
kidne/9 and other organs. Lactated Ringer's solution has a low 
potassium content and is nearly isotonic. 
Chilled special solutions with an electrolyte composition simi-
lar to that in cells were shown in 1969 by Collins and coworkersll 
to extend the permissible limit of cold renal ischemia beyond 
that achievable with isotonic solutions. The same effect has been 
shown with Iivers .3 Cardiac surgeons have cooled the heart with 
various cardioplegic solutions haVing potassium concentrations of 
about 20 mEq/L. The simplest way to cool any organ internally 
is by preliminary in situ infusion of lactated Ringer's solution and 
then infuSing the individual organ with specified amounts of a 
special solu tion after its removal. 
Graft Nephrectomy 
A complete midline inCISion is made from the suprasternal 
notch to just above the symphysis pubis (Fig 38-1). The long 
incision provides good exposure for removal of the heart, both 
kidneys , the liver, and other thoracoabdominal viscera. All of the 
multiple organ removals can be envisioned as modifications of 
the evisceration techniques for cadaver kidney removal that were 
described by Ackermann and Snell l and by Merkel et a\. 29 
at fusion of 
and 
__ _ Pubis 
The extraperitoneal space is entered by incising the peritoneal 
reflection and sweeping up the ascending colon, cecum, and dis-
tal small bowel (Fig 38-2). After freeing the ureters, distal aorta, 
and inferior vena cava, the kidneys can be infused in situ with a 
cold solution through an aortic cannula (Fig 38-3). Almost all of 
the infusate will pass into the kidneys if the superior mesen teric 
artery and celiac axis are occluded (see Fig 38-3). 
The washed-out kidneys are now removed from below (Fig 
38-4). All tissues passing posteriorly are cut, staying close to the 
ligaments and muscles covering the vertebral bodies (see Fig 38-
4) and continuing superiorly. 
After the kidneys and/or other organs have been cooled and 
excised, segments of the i!iac arteries and veins are routinely 
removed and placed in a cold tissue culture solution for refrig-
eration. Such grafts can be lifesaving in the event of unexpected 
technical problems in the recipient. 53 
Total Hepatectomy 
Removal of the liver requires only minor modifications of the 
foregoing basic technique . If the anatomy is normal, the splenic 
and left gastric arteries are dissected, ligated , and divided (Fig 
38-5), and the celiac axis is dissected as far back toward the aorta 
as is convenient. The aorta is clamped above the celiac axis (Fig 
38-6). After ligating and dividing the gastroduodenal artery and 
Ascendong coton ond 
cecum reflected 
upward , 
, 
R ureler 
ligated 
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Ftg 38-2.-Nephrectomy: preliminary steps for in situ 
infuSion of kidneys in a cadaveric donor (pronounced dead by 
neurologic criteria) with an effective circulation. (Used by 
permission. 52) 
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Allernative sites -
for aortic 
clomping, 
Fig 38-3,-Nephrectomy: in situ infusion of kidneys with cold preservation 
fluid through the distal aorta, with a venous bleed-off from the distal inferior vena 
Preservotion 
fluId 
cava. The aOrla is clamped proximally at one of the sites shown in Figure 38-3. 
(Used by permission. 52) 
K,dney and Gerata'. 
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Fig 38-4.-Nephrectomy: removal of perfused 
kidneys en bloc. The kid~eys and great vessels are 
held anterior to the plane of scissor dissection. (Used 
by permission. 52) 
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R go 
Common 
rranseCled 
Perlal vein 
\ 
\ 
\ 
Rg 38--5.-Hepatectomy: hilar dissection and transection of Ihe common duct 
as an initial step in multiple organ harvesting. Note that the splenic vein (or alter-
;/ Lower Ihoroclc aorta encircled 
for evenluol cross clamp 
Preservahan fluid 
- Upper abdominal OOriO 
enc"cled (ollernallve 
cross clamp .. ile) 
__ _ SpleniC v. Wllh ca nnula 
~~r:1pK~~-=::::::- Sup. mesenleric v 
enc"cl e d 
natively lhe superior mesenteric vein) is cannulated for eventual delivery of pres-
ervation fluid . (Used by permissions,) 
Fig 38--6.-ln situ infusion technique used when the kidneys and liver are 
removed from the same donor. (Rga, right gastric artery; Gda, gastroduodenal 
Cannula in 
,splen IC v 
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./ 
Preserva tion ~_ 
fluid 
artery; PV, portal vein; SA, splenic artery; SV, splenic vein; SMV, superior meso 
enteric vein.) (Used by permission.52) 
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Fig 38-7.-Final steps if the heart is to be removed in combination with ne-
phrectomies and/or hepateclomy. See text for details . (Used by permission. 52) 
the right gastric artery, the portal vein is cleaned inferiorly to 
the junction of the splenic vein and the superior mesenteric 
vein . The liver is infused through the splenic vein as well as 
through the aorta (see Fig 38-6). 
The cooled liver is quickly excised and refrigerated. The 10 or 
15 minutes required to remove the liver are not harmful to the 
kidneys , which are not subjected to any warm ischemia whatso-
ever, because they have been cooled in situ . With the liver out, 
removal of the kidneys en bloc is carried out as described under 
graft nephrectomy. The renal excision,is greatly facilitated by the 
absence of the liver. Vascular grafts are removed as described 
previously . 
Removal of the Heart 
The simple preparatory steps described under graft nephrec-
tomy or hepatectomy are completed. The cardiac team now as-
sumes command. The principle that is followed is to disconnect 
the thoracic and abdominal aortic circulation by aortic cross-
clamping at one of the encirclement levels just above or below 
the diaphragm (Fig 38-7) at the precise moment of cessation of 
heartbeat. with immediate graft cooling of both abdominal and 
thoracic viscera. 
The way in which the organs are removed with multiple graft 
procurement defines an explicit priority list of heart, liver, and 
kidneys in that order. The heart must function immediately upon 
transplantation, and the liver must function within a few hours, 
whereas immediate function of renal grafts is not a prerequisite 
for survival of the recipient. 
Hearts and livers from multiple harvests have been of uni-
formly good quality. The rate of acute tubular necrosis requiring 
hemodialysis in patients whose kidneys were obtained at multi-
ple organ harvests has been only one fifth of the lowest incidence 
reported after the harvest of kidneys alone. 47,48 The exceedingly 
low rate of renal injury could reflect the acceptance of only very 
good donors for hearts and livers, or the fact that there is a high 
intensity of skilled surgical and anesthesiologic input in such 
cases. However, the most important factor probably is the sys-
tematic use of a superior method of nephrectomy that totally 
precludes any period of warm ischemia for all organs and that 
eliminates the manipulation that can unknowingly damage the 
organs if vascular skeletonization techniques are used. 
Other Organ Combinations 
The general principles herein described can be applied to graft 
pancreatectomy or intestinal graft removal. If the whole pancreas 
is transplanted, as we recommend, the combination of liver and 
pancreas removal is incompatible. 
Preservation by Continuous Perfusion 
The organs harvested with this technique are usually kept in 
"slush" at near 0 C until their transplantation within time limits 
of 6, 8, and 48 hours for the heart , liver, and kidneys, respec-
tively. Sophisticated techniques for continuous perfusion of all 
these organs have been developed, but have been Widely used 
only for kidney grafts. The perfusion technique for kidneys was 
described by Belzer et aI., 2 using an asanguinous and oncotically 
controlled fluid. The method is a good one, but the quality of 
preservation in the first 2 days has not been markedly better 
than with the simpler infusion and slush me thod. Better contin-
uous perfusion techniques should permit the extension of pres-
ervation times of all organs. 
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Kidney Transplantation 
Selection and Evaluation of Patients 
for Renal Transplantation 
PEDIATRIC RENAL TRANSPLANTATION is increasingly accepted 
treatment for end-stage renal disease in the child. In 1968, 
Merrill45 listed several factors believed to be important in recip-
ient selection, including (1) age, (2) failure to respond to good 
medical management, (3) absence of reversible factors, (4) nor-
mal lower urinary outflow tract, (5) absence of major extrarenal 
complications, (6) absence of malnutrition, (7) absence of pancy-
topenia, and (8) ABO compatibility. Many of these limitations are 
arbitrary and unnecessarily restrictive. At the University of Min-
nesota, there is one primary indication for renal transplantation: 
renal failure that cannot be corrected. Absolute contraindications 
to transplantation are (1) ABO incompatibility, (2) cytotoxic anti-
bodies against donor lymphoid cells, (3) active infection, and (4) 
malignancy not under control. Specific problems in the pediatric 
transplant population are addressed as clinical experience grows. 
This philosophy has led to transplantation in younger and smaller 
children than previously seemed possible. It is now common for 
us to accept infants under 6 months of age and 6 kg in body 
weight as recipients of adult kidneys. These advances in surgical 
technology and medical management, which do not compromise 
patient or graft survival (see below), have profound implications 
for patient selection. In the past, the dialysis support of the neo-
nate or very young infant, with the aim of achieving 1 year of 
age and 6-8 kg in body weight before transplantation, was so 
formidable as to discourage all but the most aggressive and per-
sistent physicians from undertaking this commitment. With re-
cent progress in infant peritoneal and hemodialysis, improved 
understanding of nutrition problems and renal osteodystrophy in 
small uremic children, and with the availability of earlier trans-
plantation, this undertaking is no longer unreasonable. However, 
because infants in renal failure or with congenital nephrotic syn-
drome often manifest delay in psychomotor development, the 
task of applying exclusion criteria based upon estimated intellec-
hlal potential has become substantially more difficult in that such 
prognostication in young infants is even less dependable than in 
older infants and young children. 
Because the limits of recoverability of psychomotor potential 
currently are undefined, children with psychomotor retardation 
of undefined cause are accepted by us as transplant candidates. 
On the other hand, children with marked retardation from a spe-
cific cause, such as birth asphyxia, structural abnonnalities, and 
metabolic disorders, have been excluded. In anv case, children 
with these disorders rarely present as candidat~s for transplan-
tation. Using liberal acceptance criteria, approximately 97% of 
the patients evaluated are deemed suitable candidates for trans-
plantation. Experience since 1968 with over 200 patients less 
than 18 years old has demonstrated the advances and improved 
results of transplantation in infants12. 15.37 and children. 
Although it is desirable to postpone transplantation until the 
patient requires dialysis, some children require transplantation 
earlier. In children with the congenital nephrotic syndrome, 
there may be failure to thrive despite aggressive attempts at 
medical management with diuretics, nutritional supplementa-
tion, and control of frequent infections. Failure of such therapy 
for 2-3 months has led to transplantation in these patients with 
serum creatinine levels as low as 1 mg/dl. 38 Further, it is our 
impression that patients with primary hyperoxaluria should un-
dergo transplantation early, avoiding protracted periods of renal 
insufficiency or dialysis that may contribute to increased extrare-
nal accumulations of oxalate in stones, which can provide sources 
of oxalate that can com promise the transplanted kidney. 60 
Finally, there is evidence accumulating that uremia in infancy in 
a substantial proportion of patients may be associated with pro-
gressive deterioration in eNS structure and function. 2. 23. 59 Al-
though this may eventually constitute a compelling argument for 
earlier transplantation, considerable further study is required be-
fore clear therapeutic guidelines emerge. 
In general, transplantation is not recommended in uremic 
children with growth failure. Aggressive nutrition, including gav-
age feeding of infants and children with low caloric intake, leads 
to slow but steady growth, even in children with advanced ure-
mia. We and others have carried out successful transplantation 
into ileal loops in children with abnormal lower urinary tracts 
because of congenital anomalies or neuropathic bladders. Chil-
dren with previous malignancies (e. g., bilateral Wilms tumors) 
